These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

739 related items for PubMed ID: 8201386

  • 1. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
    Krigel RL, Palackdharry CS, Padavic K, Haas N, Kilpatrick D, Langer C, Comis R.
    J Clin Oncol; 1994 Jun; 12(6):1251-8. PubMed ID: 8201386
    [Abstract] [Full Text] [Related]

  • 2. A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer.
    Strauss GM, Lynch TJ, Elias AD, Jacobs C, Kwiatkowski DJ, Shulman LN, Carey RW, Grossbard ML, Jauss S, Sugarbaker DJ.
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):70-4. PubMed ID: 7544029
    [Abstract] [Full Text] [Related]

  • 3. The role of hematopoietic growth factors in support of ifosfamide/carboplatin/etoposide chemotherapy.
    Crawford J, George M.
    Semin Oncol; 1995 Jun; 22(3 Suppl 7):18-22. PubMed ID: 7541916
    [Abstract] [Full Text] [Related]

  • 4. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients.
    Steward WP, von Pawel J, Gatzemeier U, Woll P, Thatcher N, Koschel G, Clancy L, Verweij J, de Wit R, Pfeifer W, Fennelly J, von Eiff M, Frisch J.
    J Clin Oncol; 1998 Feb; 16(2):642-50. PubMed ID: 9469353
    [Abstract] [Full Text] [Related]

  • 5. Phase II study of ifosfamide, carboplatin, etoposide and GM-CSF in small cell lung cancer.
    Thongprasert S.
    J Med Assoc Thai; 2000 May; 83(5):549-53. PubMed ID: 10863902
    [Abstract] [Full Text] [Related]

  • 6. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis.
    Langer CJ, Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA, Engstrom PF, Litwin S, Ozols RF.
    J Clin Oncol; 1995 Aug; 13(8):1860-70. PubMed ID: 7543559
    [Abstract] [Full Text] [Related]

  • 7. Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
    Chang AY, Boros L, Garrow GC, Asbury RF, Hui L.
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):74-7. PubMed ID: 8677454
    [Abstract] [Full Text] [Related]

  • 8. Phase I trial of etoposide, carboplatin, and GM-CSF in extensive small-cell lung cancer: a Cancer and Leukemia Group B study (CALGB 8832).
    Luikart SD, Herndon JE, Hollis DR, MacDonald M, Maurer LH, Crawford J, Clamon GH, Wright J, Perry MC, Ozer H, Green MR.
    Am J Clin Oncol; 1997 Feb; 20(1):24-30. PubMed ID: 9020283
    [Abstract] [Full Text] [Related]

  • 9. Failure of granulocyte-macrophage colony-stimulating factor to reduce febrile neutropenia in children with recurrent solid tumors treated with ifosfamide, carboplatin, and etoposide chemotherapy.
    Marina NM, Shema SJ, Bowman LC, Rodman J, Douglass EC, Furman WL, Pappo A, Santana VM, Hudson M, Meyer WH.
    Med Pediatr Oncol; 1994 Feb; 23(4):328-34. PubMed ID: 8058003
    [Abstract] [Full Text] [Related]

  • 10. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
    Masuda N, Fukuoka M, Kudoh S, Matsui K, Kusunoki Y, Takada M, Nakagawa K, Hirashima T, Tsukada H, Yana T.
    J Clin Oncol; 1994 Sep; 12(9):1833-41. PubMed ID: 7521905
    [Abstract] [Full Text] [Related]

  • 11. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
    Masters GA, Hoffman PC, Drinkard LC, Watson S, Samuels BL, Golomb HM, Vokes EE.
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
    [Abstract] [Full Text] [Related]

  • 12. Dose-intensive ifosfamide/carboplatin/etoposide plus granulocyte-macrophage colony-stimulating factor for non-small cell lung cancer.
    Palackdharry CS, Krigel RL.
    Semin Oncol; 1994 Jun; 21(3 Suppl 4):6-11. PubMed ID: 8209278
    [Abstract] [Full Text] [Related]

  • 13. A phase I dose escalation study of multicyclic, dose-intensive chemotherapy with peripheral blood stem cell support for small cell lung cancer.
    Takahashi M, Yoshizawa H, Tanaka H, Tanaka J, Kagamu H, Ito K, Shimbo T, Chou D, Wakabayashi M, Suzuki E, Sakai K, Arakawa M, Gejyo F.
    Bone Marrow Transplant; 2000 Jan; 25(1):5-11. PubMed ID: 10654007
    [Abstract] [Full Text] [Related]

  • 14. Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.
    Langer CJ, Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA, Engstrom PF, Litwin S, Johnson S, Ozols RF.
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):18-29. PubMed ID: 7544025
    [Abstract] [Full Text] [Related]

  • 15. Paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer.
    Langer CJ, Leighton J, McAleer C, Comis R, O'Dwyer P, Ozols R.
    Semin Oncol; 1995 Jun; 22(3 Suppl 6):64-9. PubMed ID: 7541156
    [Abstract] [Full Text] [Related]

  • 16. Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer: update and preliminary survival analysis.
    Strauss GM, Lynch TJ, Elias AD, Jacobs C, Herbst R, Leong T, Lynch C, Kwiatkowski DJ, Carey RW, Grossbard ML, Skarin AT.
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-73-S12-80. PubMed ID: 9331127
    [Abstract] [Full Text] [Related]

  • 17. Phase I/II study of carboplatin and oral etoposide with granulocyte-colony stimulating factor in advanced nonsmall cell lung cancer.
    Frasci G, Perillo G, Comella G, Comella P, Polverino M, Menzella G, Persico G.
    Cancer; 1995 Apr 01; 75(7):1578-85. PubMed ID: 8826913
    [Abstract] [Full Text] [Related]

  • 18. A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors: a report of the Children's Cancer Group.
    Cairo MS, Krailo MD, Weinthal JA, Secola R, Bergeron S, van de Ven C, Blazar BR, Garrison L, Reaman GH.
    Cancer; 1998 Oct 01; 83(7):1449-60. PubMed ID: 9762948
    [Abstract] [Full Text] [Related]

  • 19. Dose escalation study of carboplatin with fixed-dose etoposide plus granulocyte-colony stimulating factor in patients with small cell lung carcinoma. A study of the Lung Cancer Study Group of West Japan.
    Katakami N, Takada M, Negoro S, Ota K, Fujita J, Furuse K, Ariyoshi Y, Ikegami H, Fukuoka M.
    Cancer; 1996 Jan 01; 77(1):63-70. PubMed ID: 8630941
    [Abstract] [Full Text] [Related]

  • 20. Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report.
    Cairo MS, Shen V, Krailo MD, Bauer M, Miser JS, Sato JK, Blatt J, Blazar BR, Frierdich S, Liu-Mares W, Reaman GH.
    J Pediatr Hematol Oncol; 2001 Jan 01; 23(1):30-8. PubMed ID: 11196267
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.